InvestorsHub Logo
Followers 38
Posts 1440
Boards Moderated 0
Alias Born 03/07/2004

Re: entdoc post# 53388

Thursday, 07/08/2010 4:20:05 PM

Thursday, July 08, 2010 4:20:05 PM

Post# of 346056
A Phase II trial evaluating T-DM1 for this use has completed patient enrollment, with interim data expected to be reported at the European Society of Medical Oncology (ESMO) meeting being held Oct. 8-12, 2010 in Milan, Italy. This trial compares T-DM1, given as a single agent, to Herceptinâ (trastuzumab) plus Taxotereâ (docetaxel).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News